Submission
Submission | Aug. 19, 2024 |
Submission [Line Items] | |
Central Index Key | 0001815442 |
Registrant Name | Kymera Therapeutics, Inc. |
Registration File Number | 333-259955 |
Form Type | S-3 |
Submission Type | 424B5 |
Fee Exhibit Type | EX-FILING FEES |
Offerings
Offerings | Aug. 19, 2024 USD ($) shares |
Offering: 1 | |
Offering: | |
Fee Previously Paid | false |
Rule 457(r) | true |
Security Type | Equity |
Security Class Title | Common stock, $0.0001 per share |
Amount Registered | shares | 6,349,692 |
Proposed Maximum Offering Price per Unit | 40.75 |
Maximum Aggregate Offering Price | $ | $ 258,749,949 |
Fee Rate | 0.01476% |
Amount of Registration Fee | $ | $ 38,191.5 |
Offering Note | (1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to this prospectus supplement has been paid in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (File No. 333-259955). (2) Includes 828,220 shares of common stock that the underwriters have an option to purchase and 3,519,159 shares of common stock that are issuable upon the exercise of the pre-funded |
Offering: 2 | |
Offering: | |
Fee Previously Paid | false |
Rule 457(r) | true |
Security Type | Equity |
Security Class Title | Pre-funded warrants to purchase common stock |
Amount Registered | shares | 3,519,159 |
Proposed Maximum Offering Price per Unit | 40.75 |
Fee Rate | 0.01476% |
Offering Note | (1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to this prospectus supplement has been paid in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (File No. 333-259955). (3) Represents the sum of the offering price of $40.7499 per pre-funded pre-funded pre-funded |
Fees Summary
Fees Summary | Aug. 19, 2024 USD ($) |
Fees Summary [Line Items] | |
Total Offering | $ 258,749,949 |
Previously Paid Amount | 0 |
Total Fee Amount | 38,191.5 |
Total Offset Amount | 0 |
Net Fee | $ 38,191.5 |